emerg
virus
major
threat
human
health
recent
outbreak
emphas
urgent
need
new
antivir
treatment
sever
pathogen
virus
consider
effort
focus
vaccin
develop
howev
epidem
infect
individu
need
treat
urgent
highthroughput
screen
clinic
test
compound
provid
rapid
mean
identifi
undiscov
antivir
function
wellcharacter
therapeut
repurpos
drug
bypass
part
earli
cost
time
need
valid
author
review
describ
recent
effort
find
broad
spectrum
antivir
drug
repurpos
chosen
sever
candid
propos
strategi
understand
mechan
action
determin
resist
antivir
develop
infect
cell
virus
constant
threat
human
anim
plant
hundr
virus
caus
diseas
human
treatment
emerg
reemerg
virus
public
health
concern
howard
fletcher
pathogen
rift
valley
fever
viru
rvfv
dengu
viru
denv
west
nile
viru
wnv
yellow
fever
viru
yfv
ebola
viru
ebov
sarsand
merscov
zika
viru
zikv
crimean
congo
hemorrhag
fever
viru
cchfv
sever
fever
thrombocytopenia
syndrom
viru
sftsv
chikungunya
viru
chikv
influenza
viru
iav
recent
outbreak
virus
summar
tabl
intern
travel
migrat
global
commerc
technolog
industri
agricultur
develop
climat
chang
favor
emerg
reemerg
virus
could
easili
spread
potenti
becom
pandem
jone
et
al
clear
exampl
potenti
emerg
viru
becom
pandem
emerg
human
immunodefici
viru
hiv
http
aidsinfounaidsorg
sharp
hahn
cure
hiv
although
antiretrovir
treatment
control
viru
barresinoussi
et
al
case
influenza
viru
vaccin
antivir
drug
howev
virus
constantli
chang
antivir
resist
emerg
human
infect
new
avian
influenza
viru
china
caus
consider
concern
due
pandem
potenti
viru
su
et
al
expert
consid
viru
could
gain
abil
spread
among
peopl
trigger
global
epidem
su
et
al
tanner
et
al
due
reason
urgent
need
new
effici
broadspectrum
antivir
howard
fletcher
schor
einav
tradit
strategi
drug
develop
one
viru
one
drug
base
develop
molecul
specif
target
viral
protein
success
certain
virus
like
hiv
hepat
c
viru
hcv
barresinoussi
et
al
li
de
clercq
fact
approv
antivir
treatment
target
viral
protein
thu
usual
quit
viru
specif
howev
direct
act
antivir
daa
drawback
develop
new
therapeut
compound
time
resourc
consum
dimasi
et
al
whole
process
discoveri
new
drug
potenti
treat
specif
diseas
condit
approv
use
human
take
sever
year
averag
year
nosengo
first
stage
drug
discoveri
take
year
preclin
studi
usual
anim
model
carri
studi
aim
test
effici
safeti
molecul
suitabl
model
test
human
go
year
molecul
shown
promis
result
clinic
trial
human
start
trial
phase
phase
iii
usual
last
year
final
molecul
success
pass
process
need
get
approv
appropri
agenc
end
estim
candid
molecul
success
pass
whole
process
ad
cost
drug
develop
billion
dollar
case
dimasi
et
al
one
viru
one
drug
strategi
cost
effici
approach
addit
use
daa
easili
lead
appear
drug
resist
virus
due
elev
mutat
rate
virus
iyidogan
anderson
menendezaria
et
al
peral
et
al
circumv
limit
strategi
aim
develop
molecul
target
host
cellular
factor
need
viral
replic
although
virus
also
find
way
use
altern
rout
replic
host
emerg
resist
virus
less
like
lin
gallay
zeisel
et
al
addit
approach
focus
host
cellular
pathway
need
viral
replic
favor
develop
broad
spectrum
antivir
famili
virus
share
certain
cellular
pathway
thu
drug
inhibit
specif
cellular
target
could
work
sever
virus
drawback
drug
inhibit
host
cell
target
higher
chanc
produc
undesir
side
effect
patient
compar
drug
target
viral
protein
drug
repurpos
reposit
altern
approach
lead
less
costli
faster
approv
new
treatment
viral
infect
mercorelli
et
al
clear
advantag
drug
reposit
tradit
drug
develop
sinc
reposit
drug
alreadi
pass
signific
number
test
safeti
known
risk
failur
reduc
although
reposit
drug
like
skip
phase
clinic
trial
still
need
go
phase
ii
iii
trial
test
efficaci
new
condit
nosengo
instanc
drug
might
lost
patent
case
gener
medicin
case
new
formul
new
medic
use
exist
old
drug
second
medic
use
patent
obtain
hand
increas
implic
practic
physician
research
academ
center
clinic
trial
also
help
repurpos
drug
nosengo
addit
thousand
drug
alreadi
pass
clinic
trial
confirm
safe
use
human
howev
reason
lack
poor
effici
treat
condit
scrutini
reach
market
collect
drug
anoth
sourc
potenti
antivir
sever
drug
market
test
potenti
use
broad
spectrum
antivir
treatment
tabl
mani
compound
shown
promis
result
preclin
studi
summar
main
result
antivir
mechan
select
candid
reposit
broad
spectrum
antivir
drug
digoxin
cardiac
glycosid
cardioton
steroid
use
treat
certain
heart
condit
includ
heart
failur
atrial
fibril
atrial
flutter
paroxysm
atrial
tachycardia
gheorghiad
et
al
cardiac
glycosid
compris
larg
famili
natur
compound
share
common
steroid
structur
digoxin
first
isol
foxglov
plant
digitali
lanata
although
foxglov
plant
extract
use
ancient
time
treat
heart
condit
gheorghiad
et
al
digoxin
shown
block
na
k
atpas
rais
intracellular
na
level
increas
intracellular
na
lead
increment
intracellular
due
inhibit
na
ca
exchang
elev
intracellular
ultim
lead
increas
contract
cardiac
muscl
smith
inhibit
na
k
atpas
shown
effect
multipl
signal
cascad
modul
neighbor
tyrosin
kinas
includ
src
ultim
affect
gene
express
nesher
et
al
thu
cardiac
glycosid
spotlight
drug
repurpos
studi
shown
potenti
use
digoxin
cardiac
glycosid
treat
cancer
prassa
diamandi
cardiac
glycosid
induc
apoptosi
divers
cancer
cell
multipl
mechan
includ
inhibit
na
k
atpas
suppress
nuclear
factorkappab
inhibit
topoisomeras
ii
ishida
et
al
vaklava
et
al
perform
chemic
screen
insect
cellbas
report
system
cardiac
glycosid
digoxin
identifi
specif
inhibitor
retino
acid
receptorrel
orphan
nuclear
receptor
transcript
activ
huh
et
al
requir
induct
transcript
manifest
h
autoimmun
diseas
mice
studi
indic
digoxin
deriv
could
use
therapeut
agent
attenu
inflammatori
lymphocyt
function
autoimmun
diseas
recent
studi
shown
digoxin
cardiac
glycosid
potenti
use
antivir
wong
colleagu
report
suppress
replic
digoxin
wong
et
al
digoxin
shown
accomplish
antiretrovir
effect
two
mechan
induc
overspl
rna
reduc
accumul
viral
rna
encod
structur
protein
need
new
virion
assembl
select
inhibit
express
regulatori
protein
rev
studi
show
digoxin
exert
antihiv
effect
alter
function
subset
sr
protein
conserv
famili
serin
argininerich
protein
involv
rna
splice
screen
drug
librari
compound
inhibit
late
step
replic
cycl
also
identifi
sever
member
cardiac
glycosid
famili
laird
et
al
cardiac
glycosid
digoxin
ouabain
also
shown
impair
replic
human
cytomegaloviru
hcmv
herp
simplex
viru
hsv
belong
famili
dsdna
virus
herpesvirida
dodson
et
al
hartley
et
al
kapoor
et
al
inhibit
happen
earli
postentri
step
produc
grosso
et
al
although
precis
mechan
action
fulli
clear
drug
alter
viral
mrna
process
block
replic
viral
dna
synthesi
cardiac
glycosid
like
procillaridin
bufallin
covallatoxin
digitoxin
abl
inhibit
hepat
b
viru
hbv
cell
cultur
okuyamadobashi
et
al
studi
howev
digoxin
show
antihbv
effect
digoxin
also
inhibit
alphavirus
singlestrand
positivesens
rna
virus
like
chikungunya
ross
river
viru
sindbi
viru
well
unrel
mammalian
orthoreoviru
polyseg
doublestrand
rna
viru
vesicular
stomat
viru
rhabdovirida
famili
negativesens
rna
viru
ashbrook
et
al
studi
digoxin
shown
impair
chikungunya
infect
earli
postentri
step
coronavirus
like
felin
infecti
periton
viru
murin
hepat
viru
merscov
inhibit
ouabain
bufalin
burkard
et
al
antivir
effect
cardiac
glycosid
observ
drug
ad
prior
infect
infect
affect
drug
ad
h
postinfect
suggest
virus
drug
act
entri
step
sunitinib
small
molecul
inhibit
multipl
tyrosin
kinas
receptor
like
vascular
endotheli
growth
factor
receptor
vegfr
plateletderiv
growth
factor
receptor
fibroblast
growth
factor
receptor
epiderm
growth
factor
receptor
mendel
et
al
sun
et
al
sunitinib
approv
fda
treatment
cancer
atkin
et
al
recent
studi
shown
sunitinib
may
also
broad
spectrum
antivir
activ
intracellular
traffick
virus
reli
endocyt
exocyt
cellular
pathway
process
usual
requir
signal
transduct
suggest
kinas
inhibitor
may
antivir
activ
block
endocyt
exocyt
pathway
bind
hcv
core
protein
adaptor
protein
subunit
essenti
hcv
assembl
phosphoryl
adaptor
associ
kinas
cycl
gassoci
kinas
gak
regul
interact
neveu
et
al
also
shown
cotraff
hcv
viral
particl
within
cell
bekerman
et
al
studi
show
sunitinib
prevent
hcv
entri
assembl
appar
inhibitori
effect
gak
effect
hcv
rna
replic
erlotinib
anoth
anticanc
drug
also
inhibit
hcv
entri
assembl
similarli
sunitinib
andor
erlotinib
restrict
infect
denv
ebov
vitro
murin
anim
model
potent
vitro
antivir
activ
zikv
wnv
chikv
junin
viru
junv
respiratori
syncyti
viru
rsv
bekerman
et
al
pu
et
al
sunitinib
also
shown
inhibit
hcmv
infect
cell
cultur
cai
et
al
infect
rest
cell
guo
et
al
although
studi
show
potenti
antivir
activ
sunitinib
drug
also
inhibit
protein
kinas
r
pkr
synthetas
oa
rnase
l
system
act
antivir
effector
respons
type
interferon
jha
et
al
capac
sunitinib
block
two
innat
immun
pathway
could
hamper
potenti
use
antivir
develop
select
gak
inhibitor
could
bypass
hurdl
sens
screen
librari
base
bicycl
heteroaromat
flat
scaffold
design
discov
novel
ligand
gak
led
identif
hit
compound
base
isothiazolo
pyridin
scaffold
kovackova
et
al
isothiazolo
pyridin
deriv
low
nanomolar
affin
gak
exhibit
inhibitori
activ
hcv
cell
cultur
act
level
viral
entri
assembl
kovackova
et
al
chloroquin
cq
weak
base
deriv
easili
enter
cell
accumul
acid
compart
like
endosom
lysosom
transgolgi
network
vesicl
rais
ph
thome
et
al
clinic
cq
use
treatment
nonresist
malaria
slater
white
addit
cq
proven
antiinflammatori
properti
approv
clinic
manag
autoimmun
diseas
rheumatoid
arthriti
lupu
erythematosu
rainsford
et
al
mani
virus
use
acid
organel
point
replic
cycl
prompt
studi
cq
hydroxyl
analogu
hydroxychloroquin
hcq
potenti
antivir
drug
cq
hcq
test
prove
vitro
instanc
vivo
antivir
activ
sever
virus
describ
two
main
mechan
action
describ
antivir
activ
cq
albari
one
hand
mani
virus
use
acid
endocyt
vesicl
like
endosom
lysosom
enter
host
cell
acidif
vesicl
trigger
conform
chang
envelop
protein
viru
induc
fusion
viral
cellular
membran
deliveri
virion
content
cell
cq
rais
ph
vesicl
imped
conform
chang
need
viral
entri
uncoat
block
infect
cq
also
shown
impair
matur
viral
protein
golgi
network
block
action
phdepend
enzym
like
proteas
glycosyltransferas
need
matur
process
antiretrovir
effect
cq
cell
cultur
shown
occur
inhibit
glycosyl
hiv
viral
particl
savarino
et
al
antivir
activ
cq
sarscov
seem
relat
poor
glycosyl
sarscov
receptor
vincent
et
al
cq
report
inhibit
denv
replic
block
cleavag
prm
protein
occur
acid
compart
boonyasuppayakorn
et
al
randolph
et
al
cq
deriv
report
strong
antivir
activ
sarscov
merscov
differ
cell
line
ic
rang
de
wild
et
al
dyall
et
al
keyaert
et
al
vincent
et
al
howev
sarscov
mous
model
cq
treatment
reduc
viru
titer
lung
barnard
et
al
studi
report
inhibitori
effect
cq
influenza
virus
iav
vitro
concentr
similar
dose
use
malaria
treatment
ooi
et
al
howev
suscept
iav
cq
seem
depend
ph
requir
virus
electrostat
potenti
hemagglutinin
di
trani
et
al
mous
model
infect
iav
cq
treatment
dramat
increas
surviv
infect
mice
administ
therapeut
administ
prophylact
treatment
yan
et
al
furthermor
random
doubleblind
placebo
control
clinic
trial
protect
influenza
infect
paton
et
al
dengu
viru
wnv
replic
also
report
block
cq
cell
cultur
boonyasuppayakorn
et
al
faria
et
al
recent
studi
demonstr
efficaci
cq
prophylact
therapeut
treatment
aotu
monkey
inocul
denv
faria
et
al
howev
doubleblind
placebocontrol
clinic
trial
vietnam
fail
show
benefici
impact
cq
treatment
outcom
infect
except
modest
reduct
percentag
patient
develop
dengu
hemorrhag
fever
cqtreat
arm
tricou
et
al
chloroquin
also
exhibit
antivir
activ
zikv
anoth
member
flavivirida
famili
differ
cell
line
ic
around
delvecchio
et
al
addit
studi
demonstr
chloroquin
protect
mice
zikv
infect
shiryaev
et
al
cq
also
report
inhibit
chikv
cell
cultur
dose
depend
manner
ad
earli
point
infect
sourisseau
et
al
although
studi
therapeut
index
drug
cell
cultur
low
result
point
potenti
use
cq
treatment
chikv
infect
howev
clinic
trial
french
reunion
island
outbreak
chikv
test
efficaci
safeti
cq
treatment
show
evid
signific
antivir
effect
cq
treat
patient
compar
placebo
treat
patient
de
lamballeri
et
al
lack
antivir
effect
could
due
high
viral
load
serum
patient
acut
phase
infect
rather
narrow
therapeut
index
cq
leav
littl
room
dose
adjust
could
allow
use
cq
therapeut
treatment
acut
chikungunya
infect
nonetheless
cell
cultur
viral
titer
lower
cq
strongli
inhibit
chikv
infect
concentr
achiev
plasma
individu
cq
treatment
malaria
suggest
cq
could
use
prophylact
treatment
chikungunya
outbreak
prevent
transmiss
khan
et
al
howev
recent
studi
nonhuman
primat
show
chloroquin
treatment
exacerb
diseas
andor
suppress
antivir
immun
chloroquin
treat
macaqu
compar
placebo
group
roqu
et
al
cq
hcq
shown
inhibit
hiv
replic
monocyt
cell
line
well
monocyt
primari
cell
posttranscript
step
sperber
et
al
tsai
et
al
cq
also
inhibit
virus
like
cchfv
ferrari
et
al
hepat
viru
hav
bishop
ebov
madrid
et
al
cell
line
addit
cq
shown
protect
mice
challeng
deadli
dose
ebov
madrid
et
al
cell
cultur
cq
shown
potent
antivir
activ
broad
rang
virus
case
efficaci
anim
model
infect
discuss
howev
clinic
trial
aim
test
efficaci
cq
antivir
shown
limit
antivir
effect
rather
narrow
therapeut
index
chloroquin
might
behind
limit
antivir
effect
chloroquin
clinic
trial
develop
chloroquin
deriv
lower
toxic
could
improv
effect
treatment
viral
infect
immunomodulatori
activ
cq
also
contribut
control
viral
diseas
reduc
excess
releas
cytokin
proinflammatori
mediat
cyclophilin
cypa
peptidylprolyl
isomeras
express
cytosol
schmid
cyclosporin
csa
cyclic
undecapeptid
immun
suppress
activ
mainli
target
cellular
cyclophilin
cyp
handschumach
et
al
schreiber
cypcsa
complex
inhibit
phosphatas
activ
calcineurin
need
nuclear
transloc
nuclear
factor
activ
cell
nfat
eventu
lead
block
transcript
cytokin
inhibit
cell
activ
matsuda
koyasu
csa
one
drug
approv
fda
immunosuppress
therapi
avoid
reject
organ
transplant
hartono
et
al
csa
report
antivir
activ
wide
rang
virus
includ
human
papilloma
viru
hpv
bienkowskahaba
et
al
vesicular
stomat
viru
vsv
bose
et
al
vaccinia
viru
vv
damaso
moussatch
frank
et
al
thali
et
al
wainberg
et
al
hcv
kaul
et
al
nakagawa
et
al
yang
et
al
although
immunosuppress
activ
csa
make
good
candid
antivir
treatment
csa
deriv
like
alisporivir
reduc
immunosuppress
properti
retain
abil
bind
cyclophilin
develop
prove
conserv
antivir
activ
flisiak
et
al
et
al
paeshuys
et
al
watashi
et
al
replic
certain
virus
like
hiv
hcv
hpv
vsv
vv
influenza
viru
reli
interact
cyclophilin
certain
step
replic
cycl
thu
antivir
activ
cyclosporin
csa
nonimmunosuppress
analog
virus
shown
relat
abil
bind
cellular
cyclophilin
inhibit
interact
viral
protein
bienkowskahaba
et
al
bose
et
al
damaso
moussatch
frank
et
al
kaul
et
al
nakagawa
et
al
thali
et
al
wainberg
et
al
yang
et
al
csa
also
block
replic
divers
coronavirus
de
wild
et
al
de
wild
et
al
pfefferl
et
al
nucleocapsid
protein
sarscov
specif
bind
cypa
luo
et
al
cypa
found
incorpor
sarscov
particl
neuman
et
al
howev
sirna
knockdown
cellular
cypa
cypb
main
target
csa
effect
infect
viru
suggest
either
cyclophilin
requir
viral
replic
remain
level
cellular
cyclophilin
enough
support
normal
replic
de
wild
et
al
addit
csa
csa
analog
shown
inhibit
hbv
entri
cell
watashi
et
al
howev
inhibitori
activ
independ
bind
cypa
calcineurin
correl
abil
csa
inhibit
transport
activ
sodium
taurochol
cotransport
polypeptid
ntcp
membran
protein
propos
hbv
receptor
cypa
report
interact
influenza
viru
matrix
protein
suppress
viral
replic
cell
cultur
anim
model
liu
et
al
role
cypa
viral
cycl
unclear
although
seem
act
sever
step
viral
life
cycl
isomeras
activ
cypa
seem
implic
liu
et
al
overexpress
cypa
inhibit
transloc
nucleu
liu
et
al
deplet
cypa
acceler
replic
viru
liu
et
al
addit
cypa
shown
increas
degrad
though
ubiquitin
proteasom
system
liu
et
al
effect
csa
influenza
viru
infect
also
investig
csatreat
mice
administ
dose
influenza
viru
would
lethal
untreat
mice
surviv
schiltknecht
ada
csa
also
report
inhibit
propag
sever
strain
influenza
viru
cell
cultur
block
late
step
replic
cycl
mechan
might
implic
cypadepend
independ
pathway
hamamoto
et
al
liu
et
al
et
al
global
result
point
nonimmunosuppress
csa
analog
promis
broadspectrum
antivir
advanc
csa
analogu
alisporivir
debio
evalu
phase
ii
phase
iii
clinic
trial
hcv
infect
patient
clinicaltrialsgov
identifi
promis
result
safeti
efficaci
studi
evalu
efficaci
csa
analog
reduc
immunosuppress
activ
antivir
clinic
trial
assur
antibacteri
effect
silver
metal
known
ancient
time
barillo
marx
recent
advanc
nanotechnolog
allow
introduct
silver
nanoparticl
agnp
biomed
applic
burdusel
et
al
agnp
prepar
sever
techniqu
includ
physic
chemic
biolog
method
depend
size
techniqu
use
prepar
nanoparticl
properti
toxic
vari
thorley
tetley
ullah
khan
et
al
agnp
proven
broad
antimicrobi
activ
gram
posit
gram
neg
bacteria
kim
et
al
moron
et
al
addit
studi
shown
agnp
also
antivir
activ
broad
rang
virus
includ
herp
simplex
viru
barampinto
et
al
influenza
viru
papp
et
al
xiang
et
al
hepat
b
viru
lu
et
al
lara
et
al
b
sun
et
al
rift
valley
fever
viru
borrego
et
al
dengu
viru
murugan
et
al
sujitha
et
al
tacarib
viru
speshock
et
al
antivir
mechan
action
agnp
well
defin
agnp
thought
interfer
viruscel
attach
entri
target
cell
directli
induc
structur
chang
virion
turn
noninfect
xiang
et
al
addit
agnp
enter
cell
exert
antivir
activ
interf
cellular
protein
need
viral
replic
direct
interact
viral
protein
silver
ion
ag
react
thiol
phosphat
group
present
protein
nucleic
acid
inhibit
differ
step
replic
cycl
lara
et
al
agnp
formul
topic
vagin
gel
could
use
prevent
transmiss
sexual
transmit
infect
like
hiv
hsv
studi
vitro
system
use
human
cervic
tissu
cultur
simul
vivo
condit
shown
encourag
result
inhibit
hiv
transmiss
lara
et
al
although
use
agnp
biomed
applic
seem
promis
studi
need
better
understand
potenti
fig
experiment
strategi
studi
mechan
action
antivir
drug
singl
cell
investig
origin
antivir
drug
resist
toxic
long
term
effect
human
health
environ
toxic
agnp
highli
relat
releas
ag
directli
depend
size
nanoparticl
smaller
size
higher
amount
ag
releas
ag
report
alter
mitochondri
function
chappel
grevil
kone
et
al
moreov
exposur
cell
agnp
induc
product
high
level
reactiv
oxygen
speci
ro
jnk
activ
lead
mitochondriadepend
cell
apoptosi
hsin
et
al
therefor
studi
need
better
understand
mode
action
agnp
cell
specif
toxicolog
issu
order
gener
new
effect
compound
well
use
combin
drug
treatment
differ
viral
diseas
high
content
imag
hci
popular
basic
tool
earli
drug
discoveri
multipl
diseas
research
area
carpent
hci
develop
contribut
major
advanc
robot
imag
autom
imag
process
moffat
et
al
hci
alreadi
fundament
technolog
antivir
screen
valid
bernatchez
et
al
hoenen
lowen
et
al
mudhasani
et
al
panchal
et
al
tan
et
al
moreov
recent
develop
light
electron
microscopi
signific
impact
virolog
particular
livecel
microscopi
superresolut
microscopi
correl
light
electron
microscopi
clem
imag
fundament
tool
studi
viruscel
interact
bykov
et
al
fernandez
de
castro
et
al
franci
melikyan
risco
et
al
witt
et
al
microscopi
also
power
tool
studi
antivir
clem
scientist
studi
event
level
singl
cell
cultur
fernandez
de
castro
et
al
hellstrom
et
al
tenorio
et
al
infect
anim
lowen
et
al
clem
start
show
potenti
test
antivir
chang
viral
structur
assembl
cell
treatment
effect
antivir
drug
fail
studi
detail
berger
et
al
lowen
et
al
martinez
et
al
cell
sort
clem
combin
proteom
transcriptom
lipidom
except
inform
identifi
new
target
antivir
drug
character
mechan
action
old
new
antivir
compound
understand
resist
antivir
develop
cell
fig
strategi
studi
follow
duplic
cell
cultur
infect
fluoresc
viru
treat
presenc
absenc
antivir
drug
process
either
clem
cell
sort
fluoresc
microscopi
reveal
interest
featur
singl
cell
process
ultrastructur
analysi
electron
microscopi
show
viral
structur
affect
antivir
drug
parallel
key
cell
factor
involv
cell
resist
infect
viral
escap
antivir
drug
identifi
compar
fluoresc
nonfluoresc
cell
separ
cell
sort
studi
proteom
transcriptom
lipidom
studi
cell
differenti
tissu
organoid
liu
et
al
takeb
et
al
walter
et
al
provid
physiolog
relev
cellular
system
studi
viru
infect
test
antivir
emerg
virus
major
threat
human
health
rate
new
pathogen
virus
emerg
acceler
past
fifti
year
frequent
outbreak
highlight
urgent
need
new
antivir
treatment
gener
antivir
drug
develop
focus
target
viral
compon
block
viru
entri
replic
morphogenesi
propag
modul
host
immun
respons
zhu
et
al
drug
repurpos
import
altern
review
chosen
sever
repurpos
drug
proven
antivir
activ
differ
mechan
action
digoxin
sunitinib
chloroquin
cyclosporin
silver
nanoparticl
promis
candid
broad
spectrum
antivir
could
use
combin
antivir
therapi
drug
repurpos
facilit
number
resourc
pollastri
campbel
pathogen
target
bioinformat
resourc
public
data
repositori
screen
data
structur
biolog
resourc
compound
collect
librari
small
molecul
nation
institut
health
http
wwwnihclinicalcollectioncom
ashbrook
et
al
cao
et
al
canadian
drugbank
http
wwwdrugbank
ca
larg
drug
databas
commonli
use
comput
drug
reposit
method
drugbank
contain
fda
approv
drug
clinic
trial
frequent
updat
new
inform
new
power
screen
assay
predict
tool
silico
structurebas
screen
larg
chemic
librari
identifi
potenti
inhibitor
viral
infect
includ
repurpos
compound
target
varieti
viral
protein
host
factor
abu
bakar
ng
barrow
et
al
dowal
et
al
martinez
et
al
yuan
et
al
anoth
strategi
sure
reveal
promis
candid
base
compar
data
databas
pathogen
brown
patel
sharma
et
al
databas
drug
eg
drug
inform
nation
librari
medicin
http
wwwnlmnihgovlearnaboutdrugshtml
imag
studi
combin
function
assay
show
local
intracellular
effect
new
inhibitor
panchal
et
al
combin
therapi
one
drug
one
target
necessari
minim
problem
resist
repurpos
antivir
drug
author
declar
conflict
interest
